Мы используем файлы cookie.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Продолжая использовать сайт, вы даете свое согласие на работу с этими файлами.
Glufimet
Подписчиков: 0, рейтинг: 0
Clinical data | |
---|---|
Other names | RGPU-238; Dimethyl 3-phenylglutamic acid hydrochloride; Dimethyl 3-phenylglutamate hydrochloride; 1,5-Dimethyl (2S)-2-amino-3-phenylpentanedioate hydrochloride |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C13H18ClNO4 |
Molar mass | 287.74 g·mol−1 |
3D model (JSmol) | |
| |
|
Glufimet (developmental code name RGPU-238), also known as dimethyl 3-phenylglutamate hydrochloride, is a derivative of glutamic acid (glutamate) which was developed in Russia and is related to the γ-aminobutyric acid (GABA) derivative phenibut (3-phenyl-GABA). It contains phenibut and glycine fragments in its chemical structure, has been described as a "GABA precursor", and is said to modulate the GABA and nitric oxide (NO) systems and to have antioxidant activity. It has been suggested that metabotropic glutamate receptors may also play a role in the mechanism of action of glufimet.Stress-protective effects have been described for glufimet in animals.
|
Forms | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Targets |
|
||||||||||||||
NO donors (prodrugs) |
|
||||||||||||||
Enzyme (inhibitors) |
|
||||||||||||||
Others |
|
||||||||||||||
See also: Receptor/signaling modulators |